About this trial
Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.
Eligibility criteria
Qualifiers
All sexes and genders
All ethnicities
Ages 14-21
Postpubertal (Tanner stage > 3)
Disqualifiers
Primary mental health diagnosis other than a depressive disorder according to DSM-V
Any contraindications to MRI scanning, phlebotomy, or SSRI treatment
Stimulant usage
A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes
Trial design
Treatments tested in this trial
- Trier Social Stress Test (TSST)
Treatment groups
Sponsors and collaborators
University of California, Los Angeles
Lead sponsor
University of Southern California
Collaborator
University of California, Irvine
Collaborator
Columbia University
Collaborator
Mayo Clinic
Collaborator
University of California, San Francisco
Collaborator
National Institute of Mental Health (NIMH)
Collaborator